



09 SEP, 2020

Applause for Suda cancer treatment

West Australian, Perth



Page 1 of 1

Applause for Suda cancer treatment

KATE PURNELL

Shares in Perth-based Suda Pharmaceuticals have soared after the company announced it had received an Australian patent for its cancer treatment.

Suda has repurposed the drug Anagrelide, a blood disorder medication, to treat certain solid tumour cancers.

“In drug development, patents are an important part of the

value-creation process and this grant in Australia strengthens our ability to maximise value from the Anagrelide program,” chief executive Michael Barker said.

The treatment is patented in Australia until 2035.

The intellectual property is already protected in Europe and Japan.

Suda’s stock closed 11.6 per cent higher at 4.8¢.



The treatment is patented in Australia until 2035.